ELEV

Elevation Oncology, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website elevationoncology.com
Employees(FY) 33
ISIN US28623U1016

Performance

-4.66%

+10.79%

+5.27%

-77.03%

+12.26%

YTD

-77.28%

Profile

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

Advanced Technical Analysis

Technical Analysis of ELEV 2025-01-31

The stock exhibits a generally bullish sentiment, with a strong Moving Average Score of 70 indicating positive momentum, while the Technical Score of 67 further supports this outlook. However, the Oscillators Score of 53 suggests a more neutral stance, indicating potential caution in the short term despite the overall bullish trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ELEV

Stock Rank

Recent News & Updates

2025-01-14 21:10
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year(Prnewswire)
2025-01-12 18:30
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones(Prnewswire)
2025-01-06 20:35
Why Elevation Oncology (ELEV) Is Among the Best Penny Stocks to Invest In According to Media?(Yahoo Finance)
2024-12-18 06:30
Bipartisan lawmakers appear 'aligned' on PBM, insurance reform(Yahoo Finance)
2024-12-11 18:30
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors(Prnewswire)
2024-12-04 18:30
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024(Prnewswire)
2024-11-25 18:30
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference(Prnewswire)
2024-11-05 18:30
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements(Prnewswire)
2024-10-10 00:00
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock(Yahoo Finance)
2024-10-09 01:02
Empery Asset Management's Strategic Acquisition in Elevation Oncology(Yahoo Finance)
2024-09-23 19:31
FDA grants fast track designation for Elevation Oncology's EO-3021(Pharmaceutical-business-review)
2024-09-22 19:30
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2(Prnewswire)
2024-09-02 19:30
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-08-06 19:12
Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours(Yahoo Finance)
2024-08-05 19:10
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements(Prnewswire)
2024-08-05 19:00
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2(Prnewswire)
2024-06-26 19:30
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer(Prnewswire)
2024-05-26 18:35
7 Top Stocks to Buy for Under $10: May 2024(Investorplace)
2024-05-13 19:53
Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target(Yahoo Finance)
2024-05-06 19:30
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference(Prnewswire)
2024-05-06 02:06
How the Medical Industry Could Produce the Biggest AI Stock Winners(Investorplace)
2024-05-02 01:54
ELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024(Investorplace)
2024-05-01 19:30
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements(Prnewswire)
2024-04-10 18:40
7 Top Stocks Under $7(Yahoo Finance)
2024-04-08 04:30
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024(Prnewswire)
2024-03-28 01:15
13 Hot Stocks to Invest in According to Wall Street Analysts(Insidermonkey)
2024-03-07 00:54
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023(Yahoo Finance)
2024-03-06 01:51
ELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023(Investorplace)
2024-03-05 18:30
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements(Prnewswire)
2024-03-05 05:00
Trim the Fat: 3 Overbought Stocks Poised for a Pullback(Yahoo Finance)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.